Skip to main content

Advertisement

Table 1 Demographic variables, clinical scores, and cerebrospinal fluid biomarker values at baseline examination, separated by diagnostic group

From: A language-based sum score for the course and therapeutic intervention in primary progressive aphasia

  HC nfvPPA svPPA lvPPA  
N Mean ± SD
range
N Mean ± SD
range
N Mean ± SD
range
N Mean ± SD
range
p value
Gender (female/male)   16/12   14/14   12/5   7/6 0.388
Handedness (left/right/mix)   1/26/1   3/25/0   1/15/1   1/11/1 0.688
Education (years) 27 13.89 ± 2.83
8–18
27 12.56 ± 3.41
4–20
16 14.69 ± 4.03
8–24
13 13 ± 3.51
8–20
0.140
Age at baseline (years) 28 67.72 ± 8.08
49.8–78.7
28 67.70 ± 7.72
51.5–78.2
17 63.26 ± 6.44
53.4–77.3
13 67.03 ± 5.25
57.8–73.8
0.073
Age of initial symptoms (years)    27 65.33 ± 8.35
47–78
14 58.36 ± 7.08
49–75
13 62.85 ± 5.93
54–72
0.022
Disease duration (years)    27 2.60 ± 1.78
0.2–8.9
14 4.01 ± 1.62
1.7–6.7
13 4.18 ± 4.68
0.4–17.7
0.040
MMSE 28 28.96 ± 0.79
27–30
26 22.73 ± 6.13
9–30
16 23.19 ± 5.47
12–30
13 20.23 ± 6.29
10–27
0.385
CDR 28 0.04 ± 0.13
0–0.5
22 2.77 ± 2.87
0–13
14 3.57 ± 2.76
0.5–10
10 3.0 ± 2.93
0–8.5
0.461
FTLD-CDR 28 0.05 ± 1.58
0–0.5
22 4.98 ± 3.64
0.5–18
14 5.79 ± 3.48
2.5–12.5
10 4.75 ± 3.59
1–11
0.561
Tau    19 456 ± 281
139–1045
13 322 ± 125
102–493
7 651 ± 403
208–1373
0.194
ptau    18 55 ± 30
24–141
13 47 ± 14
22–76
7 102 ± 71
16–239
0.091
Abeta1–42    19 585 ± 293
336–1376
13 866 ± 393
330–1601
7 525 ± 236
125–825
0.067
  1. p values correspond to Kruskal-Wallis tests, comparing the three primary progressive aphasia subgroups
  2. All cerebrospinal fluid levels are measured in pg/ml
  3. CDR Clinical Dementia Rating Scale, FTLD-CDR frontotemporal lobar degeneration-modified Clinical Dementia Rating Scale, HC healthy controls, lvPPA logopenic variant primary progressive aphasia, MMSE Mini-Mental State Examination, nfvPPA nonfluent variant primary progressive aphasia, ptau phospho tau, svPPA semantic variant primary progressive aphasia